Eureka Therapeutics Announces License with the National Cancer Institute to Advance GPC2 ARTEMIS® T Cell Therapy for Neuroblastoma
Emeryville, California, October 18, 2022 – Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat cancer, today announced it has